Find News

Filter articles

Applied Filters

Showing 31 to 40 of 1080 results

SCOTUS invites govt comment on Teva clash

US04-10-2022Staff writer

Court opens door for US solicitor general to file a brief | Hard fought ‘skinny label’ case centres on a generic medicine maker excluding patent-protected indications from its labels.

MSD prevails in diabetes drug dispute with Mylan

US29-09-2022Muireann Bolger

MSD, known as Merck in the US and Canada, has won against a case concerning branded diabetes treatment Janumet XR at the US Court of Appeals for the Federal Circuit.

Federal Circuit denies Novartis’ bid to halt generics

US29-09-2022Staff Writer

Bid to stay invalidity decision pending a SCOTUS appeal fails | Patent covers a multiple sclerosis drug | Company could take $300m hit if generics are launched.

Swiss pharma company reveals SCOTUS appeal plans

US22-09-2022Staff Writer

Federal Circuit denies petition to rehear dispute over multiple sclerosis medicine | Company will petition highest court over invalidity ruling.

Big pharma firm settles HIV drug disputes with generic makers

US13-09-2022Staff Writer

Gilead had filed patent infringement proceedings lawsuit against five companies | Drug makers will receive non-exclusive licences starting from Halloween 2031.

Generic maker urges review of $235m skinny label decision

US08-09-2022Muireann Bolger

A split Federal Circuit revived a 2017 jury verdict that Teva had infringed GSK drug | Israeli pharma firm warns of threat to availability of low-cost generic medicines.

Novartis sued over blockbuster heart failure drug

US30-08-2022Muireann Bolger

Pharma company facing lawsuit from two universities | Dispute centres on therapeutically effective co-crystals patent.

Gilead must face pay-for-delay suit

US23-08-2022Staff Writer

Class-action alleges pharma company blocked rival HIV drug | Health insurance trust convinces judge a reverse payment may have been made.

Chugai settles cancer drug patent dispute with US firm

Japan, US10-08-2022Staff Writer

Parties to withdraw lawsuit over lung cancer drug | ANDA generic would have displaced sales of patented version in Delaware, said plaintiff.

Pharma unit could get green light to launch IBS generic

US02-08-2022Staff Writer

Dispute centres on Xifaxan, used to treat irritable bowel syndrome | ‘Significant hurdle’ cleared in bringing drug to market | Bausch wins partial victory after Alvogen subsidiary failed to show that patent claims were obvious.

Showing 31 to 40 of 1080 results